ROADMAP Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study, created in 2004 (Japan), from 223 sister brands and 17477 competing brands. The ROADMAP Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study brand is owned by Daiichi Sankyo, a company listed in Francfort. The International Securities Identification Number (ISIN) of Daiichi Sankyo is JP3475350009. The sector of ROADMAP Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study is Drug Manufacturers.
Investment simulator :
Portfolio valuation
Daiichi Sankyo
(ROADMAP Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study)
over 5 years*
EUR 71.55